KAWASAKI, Japan, December 18, 2025--(BUSINESS WIRE)--PeptiDream Inc., a public Japan-based biopharmaceutical company (President: Patrick C. Reid, hereinafter "PeptiDream")(Tokyo: 4587), announced the ...
A subgroup analysis of the phase 3 FOCUS study (NCT02678572) shows that the Melphalan/Hepatic Delivery System (HDS; HEPZATO ...
− Agreement Combines PeptiDream’s Peptide Discovery Platform to Identify High Affinity Peptide Ligands with Alnylam’s Expertise in siRNA-Conjugate-Based Delivery and in Developing and Commercializing ...
LEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ...
New research shows potent in vivo gene editing in skeletal muscle of non-human primates by a novel, ultracompact CRISPR system delivered via a single AAV vector This study describes the discovery, ...
Analyzing whole-mount histologic large sections is not a new practice, but a new strategy was needed to fully characterize peripheral nerve invasion in hilar cholangiocarcinoma. Technology to evaluate ...
LEXINGTON, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ...
PeptiDream and Alnylam Announce Achievement of Key Milestone in siRNA Conjugate Discovery Collaboration Demonstrating Peptide-Ligand Mediated Targeted siRNA Delivery to Specific Extrahepatic Tissues ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback